Development of a nano-bioplatform for SARS-CoV-2 specific antigens detection
4th IEEE International Conference on Design and Test of Integrated Micro and Nano-Systems, DTS 2022
; 2022.
Article
in English
| Scopus | ID: covidwho-1973451
ABSTRACT
Lateral Flow Immunoassay (LFIA) has been employed for the development of rapid, low-cost, and relatively simple devices for Covid-19 diagnosis. The proposed approach reports the use of the antibody labeled by Gold nanoparticles for the simultaneous detection of Nucleocapsid protein and Spike protein. A comparison with the results obtained by conventional analytical methods (PCR) has been considered in a significant number of nasopharyngeal swabs;48 and 26 samples from positive and negative individuals respectively. This research provides the basis for the development of a more efficient antigenic test for SARS-Co V-2 detection as a low-cost and quick pre-screening tool. © 2022 IEEE.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
4th IEEE International Conference on Design and Test of Integrated Micro and Nano-Systems, DTS 2022
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS